Applications of Mirtazapine in Industrial Manufacturing

As a specialized API manufacturer, we supply Mirtazapine for direct use in industrial pharmaceutical production and value-added chemical synthesis. The following sections detail real, verifiable downstream application scenarios, each governed by stringent compliance frameworks and requiring precise process and compliance integration.

1. Antidepressant Finished Dosage Forms Production

Pharmaceutical manufacturers use Mirtazapine as an active pharmaceutical ingredient (API) for the manufacture of antidepressant tablets and orally disintegrating tablets (ODTs). This involves direct API incorporation in granulation and tableting lines, along with strict validation for content uniformity, dissolution, and impurity control. The production adheres to pharmacopeial standards and regional regulatory authorities, with close attention to batch consistency and stability throughout the process. The downstream use mandates Good Manufacturing Practice (GMP) and fully traceable sourcing from approved suppliers.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) API monograph 07/2016:1349
• United States Pharmacopeia USP 43–NF 38
• ICH Q7 Good Manufacturing Practice for APIs
• FDA 21 CFR Part 211 (for U.S. market)

Typical usage ratio

• API load: 7.5%–15% w/w of total tablet mass, depending on dosage strength (15 mg, 30 mg, 45 mg formulations)
• Formula adjusted for disintegration rate, tablet size, and excipient compatibility

Downstream process integration

• API introduced during wet or dry granulation phase
• Homogenization and blending with excipients pre-compression
• In-process QC for assay and blend uniformity before compression or ODT molding
• Integration in pre-defined batch record for complete traceability

Final product types

• Mirtazapine film-coated tablets (various strengths)
• Orally disintegrating tablets (ODT)
• Immediate-release tablets
• Bulk tablets or packaged units for hospital and retail pharmacies

2. Contract Manufacturing of Generic APIs

CDMOs and generic drug producers source Mirtazapine as a reference standard and bulk intermediate for the manufacture of third-party APIs and registration batches. Clients demand APIs produced under ICH Q7 compliance, supported by complete DMF dossiers and validated impurity profiles. The incorporated API undergoes re-testing for quality control and re-crystallization, where required, to meet local pharmacopeial requirements or client-specific monographs before entering final formulation or packaging stages.

Industry compliance standards

• ICH Q7 (Good Manufacturing Practice for APIs)
• WHO GMP guidelines
• Regional regulatory requirements (e.g., EMA, CDSCO, PMDA)
• DMF (Drug Master File) Type II registration

Typical usage ratio

• 100% API, supplied as pure Mirtazapine for downstream in-house milling, micronization, or further purification steps
• Standard pack sizes 5 kg–50 kg for process validation; up to 500 kg for commercial scale

Downstream process integration

• API received and checked under GMP quarantine
• May undergo further re-crystallization or micronization based on specific end-user requirements
• Inline sampling and QC testing for assay, impurities, and particle size
• Released for direct pharmaceutical formulation or onward export

Final product types

• Mirtazapine bulk API shipments for international formulators
• Micronized API powder for specialized product development
• Pre-formulated blends for specific contract clients
• Reference standards for analytical laboratories

3. Analytical Reference Materials Supply

High-purity Mirtazapine serves as a certified reference material (CRM) for analytical laboratories supporting pharmaceutical production and regulatory submissions. These materials support HPLC, GC-MS, and LC-MS/MS method development, routine quality control, and stability testing. Stringent documentation and traceability, including CoA with full analytical spectra and impurity profiling, ensure compliance with both international and local accreditation authorities. The batch is always accompanied by a statement of traceability to appropriate pharmacopeial reference standards.

Industry compliance standards

• ISO 17034:2016 (General requirements for reference material producers)
• USP Reference Standards
• Ph. Eur. Reference Standards
• ICH Q3A/B (Impurity Testing Guidelines)

Typical usage ratio

• Solution standards: 1–10 μg/mL for LC-MS or HPLC calibration
• Solid standards: 1–100 mg/batch according to QC method requirements
• Prepared in batches tailored to customer validation or routine QC batch size

Downstream process integration

• Reference standard supplied from segregated GMP lines to analytical labs
• Directly integrated into routine batch release, method validation, and stability studies
• Used for system suitability, calibration, and recovery studies in finished dosage QC
• Traceability documentation archived with batch analytical records

Final product types

• Analytical standard vials (HPLC/GC grade)
• CRM sets for method validation
• Proficiency testing samples for third-party QC labs
• System suitability mixes for regulatory filings

4. Impurity Isolation for Regulatory Toxicology Studies

Drug development programs require isolated Mirtazapine-related impurities and degradants for safety, toxicology, and genotoxicity assessment. Our facilities enable targeted synthesis and purification of specified impurity reference materials, supported by full analytical characterization, stability data, and sterile packaging suitable for in vivo or in vitro studies. Regulatory authorities emphasize full documentation and chain of custody to demonstrate the identity and purity of materials employed in safety studies and ICH stability protocols.

Industry compliance standards

• ICH Q3A (R2) Impurities in New Drug Substances
• OECD GLP (Good Laboratory Practice) Principles
• ICH M7 (R1) Assessment and Control of DNA Reactive (Mutagenic) Impurities
• Pharmacopoeial impurity reference standards guidelines (USP, Ph. Eur.)

Typical usage ratio

• Impurities typically isolated at 0.05–0.5% of API batch, depending on method sensitivity
• Purity: >98% as required for regulatory studies
• Batch sizes: 5 mg–500 mg per toxicology or stability protocol

Downstream process integration

• Isolation via preparative HPLC, flash chromatography, or targeted chemical synthesis
• Purification and lyophilization under inert atmosphere
• Characterization by 1H/13C NMR, mass spectrometry, HPLC purity, and melting point determination
• Packaged and dispatched under GLP traceability to contract research organizations and sponsor labs

Final product types

• Certified impurity reference materials (IMP-B, IMP-F, etc.)
• Isolated degradant standards for analytical QC
• GLP-compliant impurity sets for toxicology
• Special study packs for stability and genotoxicity evaluation

5. Active Pharmaceutical Ingredient (API) Reformulation Projects

Formulators and R&D groups utilize Mirtazapine to develop new delivery systems, including sustained- and controlled-release oral preparations and liquid suspensions for special patient groups. This demands rigorous pre-formulation studies for solubility, pH stability, and compatibility with matrix formers and solubilizers. The raw material must conform to project-specific release profiles and dissolution targets, verified by accelerated and real-time stability data before upscaling to pilot or commercial batches.

Industry compliance standards

• ICH Q8 (Pharmaceutical Development)
• ICH Q1A (Stability Testing of APIs and Finished Products)
• Regional pharmacopeial monographs for content and purity
• EMA/FDA guidance on modified-release formulations

Typical usage ratio

• API content: Customized to desired release profile, typically 5–12% of total formulation mass
• Adjusted according to hydrophilic matrix, coating, or suspension requirements

Downstream process integration

• Introduced during matrix preparation, fluid-bed coating, or suspension compounding
• Subjected to pilot batch simulation for release and stability
• Integrated analytical support for dissolution, content uniformity, and stress testing
• Batches tracked for process optimization and regulatory submission

Final product types

• Sustained-release tablets
• Modified-release oral capsules
• Palatable liquid suspensions (paediatric and geriatric)
• Pilot and scale-up batches for clinical studies